Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus.

  title={Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus.},
  author={Karuppiah Muthumani and Katthikbabu M Lankaraman and Dominick J. Laddy and Senthil G. Sundaram and Christopher W. Chung and Eric Y Sako and Ling Wu and Amir Hussain Khan and Niranjan Y Sardesai and Joseph J. Kim and Paluru Vijayachari and David B. Weiner},
  volume={26 40},
Chikungunya virus (CHIKV) is an emerging arbovirus and is an important human pathogen. Infection of humans by CHIKV can cause a syndrome characterized by fever, headache, rash, nausea, vomiting, myalgia, arthralgia and occasionally neurological manifestations such as acute limb weakness. It is also associated with a fatal haemorrhagic condition. CHIKV is geographically distributed from Africa through Southeast Asia and South America, and its transmission to humans is mainly through the Aedes… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 60 extracted citations

New approaches to chikungunya virus vaccine development.

Recent patents on inflammation & allergy drug discovery • 2015
View 3 Excerpts
Highly Influenced

9 The Re-Emergence of an Old Disease : Chikungunya Fever

Bordi Licia, Castilletti Concetta
View 2 Excerpts

Similar Papers

Loading similar papers…